ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CVKD Cadrenal Therapeutics Inc

0.45
0.0072 (1.63%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cadrenal Therapeutics Inc NASDAQ:CVKD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0072 1.63% 0.45 0.3311 0.60 0.51 0.44 0.46 189,461 05:00:05

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

24/01/2024 2:00pm

PR Newswire (US)


Cadrenal Therapeutics (NASDAQ:CVKD)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Cadrenal Therapeutics Charts.

PONTE VEDRA, Fla., Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that Douglas Losordo, M.D., Chief Medical Officer of Cadrenal, will participate in a fireside chat moderated by Joe Pantginis, Ph.D., Managing Director of Research at H.C. Wainwright & Co., at the Lytham Partners 2024 Investor Select Conference. Management will also host one-on-one meetings with investors.

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation. (PRNewsfoto/Cadrenal Therapeutics, Inc.)

Company Webcast
The webcasted fireside chat will take place at 11:00 am ET on Thursday, February 1, 2024. The webcast can be accessed at https://wsw.com/webcast/lytham10/cvkd/2081408 or on the Company's website at https://www.cadrenal.com/investors/. The webcast will also be available for replay following the event.

1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg/.

Further information on the conference is available at https://lythampartners.com/select2024.

ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain conditions. Tecarfarin has orphan drug and fast track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to leverage a different metabolism pathway than the oldest and most commonly prescribed Vitamin K Antagonist (warfarin). Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com 

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-investor-select-conference-on-february-1-2024-302042716.html

SOURCE Cadrenal Therapeutics, Inc.

Copyright 2024 PR Newswire

1 Year Cadrenal Therapeutics Chart

1 Year Cadrenal Therapeutics Chart

1 Month Cadrenal Therapeutics Chart

1 Month Cadrenal Therapeutics Chart

Your Recent History

Delayed Upgrade Clock